DOOR PHARMACEUTICALS, LLC

Biotech · Private

Reactive capsid assembly modulators (rCAMs) that target and destroy hepatitis B viral nucleic acid by concentrating nucleic acid-reactive chemistry at the capsid protein-tagged viral DNA/RNA.

Grants
$307K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A new class of antiviral directed at HBV capsid protein$306,500
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1361Abceutics——
1362Irex Pharma LLC——
1363CALISTA THERAPEUTICS INC——
1364DOOR PHARMACEUTICALS, LLC——
1365ADECTO PHARMACEUTICALS, INC.——
1366WEATHERWAX BIOTECHNOLOGIES CORPORATION——
1367NANO BIOTHERAPEUTICS INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Reactive Capsid Protein Associated Moleculesapplication
  • Quinazolinone Compounds For Treatment Of Hbvapplication
  • Quinazolinone Compounds For Treatment Of Hbvapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.